



Sickle Cell Disease

- Clinical/real-world application of PK activators in SCD
- Novel mechanistic studies supporting PK activation as a treatment target for SCD
- Quality of life and assessment of pain measures
- Healthcare resource utilization and other real-world evidence HEOR measures
- Long-term complications, including cognition impairment, and potential role of PK activators
- Prognostic biomarkers for long-term complications, outcomes and organ function
- Characteristics of SCD in neonatal and pediatric populations

